natgillin/translations-raw huggingface dataset:
If these test results are not normal, your doctor will discuss treatment options with you. 
Če rezultati teh testov ne bodo normalni, se bo zdravnik z vami posvetoval glede možnosti zdravljenja.
EU/1/02/240/001 10 mg 30 vials EU/1/02/240/002 15 mg 30 vials EU/1/02/240/004 20 mg 1 vial EU/1/02/240/003 20 mg 30 vials EU/1/02/240/009 25 mg 1 vial EU/1/02/240/010 25 mg 30 vials EU/1/02/240/011 30 mg 1 vial EU/1/02/240/012 30 mg 30 vials 
EU/1/02/240/001 10 mg 30 vial EU/1/02/240/002 15 mg 30 vial EU/1/02/240/004 20 mg 1 viala EU/1/02/240/003 20 mg 30 vial EU/1/02/240/009 25 mg 1 viala EU/1/02/240/010 25 mg 30 vial EU/1/02/240/011 30 mg 1 viala EU/1/02/240/012 30 mg 30 vial
This will help you to draw off as much liquid as possible. 
Tako boste lahko izvlekli kar največ tekočine.
Elderly No dose adjustment is required. 
Starejši Prilagoditev odmerka ni potrebna.
• Blood in the urine. 
• kri v urinu
The effects of SOMAVERT in pregnant women are not known, and so the use of this medicine in pregnant women is not recommended. 
Učinki zdravila SOMAVERT na nosečnice niso znani in zato uporaba tega zdravila pri nosečnicah ni priporočljiva.
Why can't I get all of the medicine out of the vial? 
Zakaj iz viale ne morem izvleči vsega zdravila?
• Do not use it-even if it looks undamaged. 
• Ne uporabite je, čeprav se zdi nepoškodovana.
(angioedema) 
(angioedem)
• Increased blood pressure. 
• zvišan krvni tlak
The safety and efficacy of SOMAVERT in children aged 0 to 17 years have not been established. 
Varnost in učinkovitost zdravila SOMAVERT pri otrocih, starih od 0 do 17 let, še nista bili dokazani.
The clinical significance of these antibodies is unknown. 
Klinični pomen teh protiteles ni znan.
• If the decision is to treat, LTs and clinical symptoms should be monitored very closely. 
• Če se odločite za zdravljenje, je treba zelo skrbno spremljati jetrne teste in klinične simptome.
- If you are diabetic, your doctor may need to adjust the amount of insulin or other medicines you are using. 
Če imate sladkorno bolezen, bo zdravnik morda moral prilagoditi odmerek insulina ali drugih zdravil, ki jih jemljete.
• Abnormal dreams. 
• nenormalne sanje
If you are unable to clean the stopper, do not use the vial. 
Če zamaška ne morete očistiti, viale ne uporabite.
It is important that you do not try to give yourself or someone else an injection unless you have received training from your healthcare provider. 
Pomembno je, da sebi ali drugim ne poskušate dajati injekcije, razen če vas je za to usposobil zdravstveni delavec.
However, breast-feeding may be continued if this medicine is discontinued: this decision should take into account the benefit of pegvisomant therapy to the mother and the benefit of breast-feeding to the child. 
Dojenje se lahko nadaljuje, če se prekine zdravljenje s tem zdravilom: pri tem je treba upoštevati korist zdravljenja s pegvisomantom za mater in korist dojenja za otroka.
- Female patients should use adequate contraception as fertility may be increased. 
Ženske bolnice morajo uporabljati ustrezno kontracepcijo, ker je plodnost lahko povečana.
Greater than 3 times ULN 
Večje od 3-kratnika ZMN
The use of this medicine in combination with other medicinal products for the treatment of acromegaly has not been extensively investigated. 
Uporaba tega zdravila v kombinaciji z drugimi zdravili za zdravljenje akromegalije ni podrobneje raziskana.
Renal clearance of pegvisomant is negligible and accounts for less than 1% of total body clearance. 
Ledvični očistek pegvisomanta je zanemarljiv; na njegov račun gre manj kot 1 % celotnega telesnega očistka.
SOMAVERT should not be used during pregnancy unless clearly necessary (see section 4.4). 
Zdravila SOMAVERT se ne sme uporabljati med nosečnostjo, razen če je nujno potrebno (glejte poglavje 4.4).
• The shape of the vial means that a very small amount of the medicine will be left behind in the vial. 
• Zaradi oblike viale zelo majhna količina zdravila ostane v njej.
LT Levels and Clinical Signs/Symptoms 
Vrednosti jetrnih testov in klinični znaki/simptomi
Dispose of the needle and syringe as instructed by your doctor, nurse or pharmacist and in accordance with local health and safety laws. 
Iglo in brizgo zavrzite, kot vam je naročil zdravnik, medicinska sestra ali farmacevt in v skladu z lokalnimi predpisi o zdravju in varnosti.
This leaflet was last revised in <{MM/YYYY}>. 
Navodilo je bilo nazadnje revidirano {MM/LLLL}
Use immediately after reconstitution. 
Uporabite takoj po pripravi.
The detailed instructions on injection procedure provided at the end of this leaflet must be followed. 
Podrobna navodila za injiciranje so navedena na koncu tega navodila.
You must tell your doctor if you have previously used other medicines for the treatment of acromegaly or medicines for the treatment of diabetes. 
Zdravniku morate povedati, če ste že prej prejemali kakšna druga zdravila za zdravljenje akromegalije ali zdravila za zdravljenje sladkorne bolezni.
Tell your doctor or pharmacist if you are using or have recently used any other medicines. 
Obvestite zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo.
The colour of the protective plastic cap is specific to the strength of the product. 
Barva zaščitne plastične zaporke je specifična za jakost zdravila.
This technique will also reduce the swirling time and allow more of the medicine to be drawn off. 
S to metodo boste prav tako skrajšali čas mešanja in izvlekli boste lahko več zdravila.
• Wash your hands with soap and water, and dry thoroughly. 
• Roke si umijte z milom in vodo in jih dobro osušite.
Do not shake vigorously, as this might cause denaturation of the active substance. 
Ne stresajte močno, ker to lahko povzroči denaturacijo učinkovine.
It must be clear and free of particles. 
Zdravilo mora biti bistro in brez delcev.
About 17% of patients will develop antibodies to growth hormone during treatment. 
Pri približno 17 % bolnikov se bodo med zdravljenjem razvila protitelesa proti rastnemu hormonu.
• Perform a comprehensive hepatic workup, including serial LTs, to determine if and when serum levels return to normal. 
• Opravite celosten pregled jeter, vključno s serijskimi jetrnimi testi, da ugotovite, ali in kdaj se ravni v serumu povrnejo na normalne.
It is not known if pegvisomant passes into breast milk. 
Ni znano, ali pegvisomant prehaja v materino mleko.
1 ml water for injections 
1 ml vode za injekcije
Treatment should be initiated under the supervision of a physician experienced in the treatment of acromegaly. 
Zdravljenje je treba začeti pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem akromegalije.
How can I prevent the medicine from foaming? 
Kako lahko preprečim, da bi se zdravilo spenilo?
Patients should be advised to use adequate contraception if necessary. 
Če je potrebno, je treba bolnicam svetovati uporabo ustrezne kontracepcijske zaščite.
Pack sizes of 1 and/or 30. 
Velikosti pakiranj po 1 in/ali30.
All patients with these tumours should be carefully monitored in order to avoid any eventual progression in tumour size under treatment. 
Vse bolnike s takšnimi tumorji je treba skrbno spremljati, da bi se izognili morebitnemu večanju tumorja med zdravljenjem.
I can see some air in the syringe. 
V injekcijski brizgi vidim nekaj zraka.
Clinical data are too limited (one reported case) to draw any conclusion on the excretion of pegvisomant in human breast milk. 
Klinični podatki so preveč omejeni (en sam poročan primer), da bi na njihovi podlagi sklepali o izločanju pegvisomanta v materino mleko pri človeku.
Upon re-administration, symptoms did not re-occur in all patients. 
Pri ponovni uporabi do vnovičnega pojava simptomov ni prišlo pri vseh bolnikih.
Treatment by pegvisomant does not reduce tumour size. 
Zdravljenje s pegvisomantom ne zmanjša velikosti tumorjev.
The therapeutic benefits of a reduction in IGF-I concentration which results in improvement of the patient's clinical condition could potentially increase fertility in female patients. 
Terapevtsko ugodno zmanjšanje koncentracije IGF-I, ki izboljša klinično stanje bolnikov, lahko pri bolnicah morda zveča plodnost.
Serum IGF-1 monitoring 
Spremljanje serumske koncentracije IGF-1
SOMAVERT is injected under the skin. 
Zdravilo SOMAVERT se injicira pod kožo.
Elevated, but less than or equal to 3 times ULN 
Zvečane, vendar manjše ali enake 3-kratniku ZMN
The powder may take a few minutes to dissolve fully, so continue swirling the vial gently until the liquid is completely clear. 
Da se prašek povsem raztopi, lahko traja nekaj minut, zato nadaljujte z nežnim mešanjem viale, dokler ni tekočina povsem bistra.
The pharmacokinetics of pegvisomant are similar in normal healthy volunteers and acromegaly patients, although heavier individuals tend to have a higher total body clearance of pegvisomant than lighter individuals, and may thus require greater doses of pegvisomant. 
Farmakokinetika pegvisomanta je pri normalnih zdravih prostovoljcih in bolnikih z akromegalijo podobna, vendar imajo težji posamezniki praviloma večji celotni telesni očistek pegvisomanta kot lažji, zato utegnejo potrebovati večje odmerke pegvisomanta.
The antibodies do not seem to stop this medicine from working. 
Kaže, da protitelesa ne preprečujejo učinka tega zdravila.
This gives your skin and the area under your skin time to recover from one injection before it receives another one in the same place. 
Tako si bosta lahko koža in predel pod njo po injekciji opomogla, preden boste na isto mesto dali drugo injekcijo.
• May treat with SOMAVERT; however, monitor LTs monthly for at least 1 year after initiation of therapy and then bi-annually for the next year. 
• Lahko zdravite z zdravilom SOMAVERT, vendar je treba vsaj 1 leto po uvedbi zdravljenja mesečno spremljati jetrne teste ter nato dvakrat letno v naslednjem letu.
The mean extent of absorption of a subcutaneous dose was 57% relative to an intravenous dose. 
Povprečni delež absorpcije subkutanega odmerka v primerjavi z intravenskim je 57 %.
It should be considered whether to continue treatment with somatostatin analogues. 
Razmisliti je treba o nadaljevanju zdravljenja z analogi somatostatina.
The list below contains adverse reactions seen in clinical trials or that were spontaneously reported, classified by system organ class and frequency. 
V spodnji preglednici so navedeni neželeni učinki, ki so bili zabeleženi v kliničnih preskušanjih ali so o njih poročali spontano; razvrščeni so po organskih sistemih in pogostnosti.
What should I do with the syringe if it has been dropped? 
Kaj naj storim z injekcijsko brizgo, če mi je padla na tla?
In cases of overdose, administration of this medicine should be discontinued and not resumed until IGF-I levels return to within or above the normal range. 
V primeru prevelikega odmerjanja je treba uporabo pegvisomanta prekiniti in se ga ne sme znova uporabiti, dokler se raven IGF-I ne vrne v ali nad normalno območje.
• If LTs normalize (regardless of whether an alternative cause of the liver dysfunction is discovered), consider cautious reinitiation of therapy with SOMAVERT, with frequent LT monitoring. 
• Če se jetrni testi normalizirajo (ne glede na to, ali odkrijete drug vzrok motnje delovanja jeter), razmislite o previdni ponovni uvedbi zdravljenja z zdravilom SOMAVERT s pogostim spremljanjem jetrnih testov.
To avoid this, use a slightly different place for your injection each time, as described in Step 2 of the ‘instructions for preparing and giving an injection of Somavert' section of this leaflet. 
Da bi to preprečili, zdravilo vsakič injicirajte nekoliko drugam, tako kot je opisano v 2. koraku poglavja "Navodila za pripravo in injiciranje zdravila Somavert" tega navodila.
Most injection site reactions characterised as localised erythemas and soreness, spontaneously resolved with local symptomatic treatment, while pegvisomant therapy continued. 
Večina reakcij na mestu injiciranja, opisanih kot lokaliziran eritem in bolečina, je z lokalnim simptomatskim zdravljenjem spontano minila, medtem ko se je zdravljenje s pegvisomantom nadaljevalo.
In clinical studies, for patients treated with pegvisomant (n=550), the majority of adverse reactions to pegvisomant were of mild to moderate intensity, of limited duration and did not require discontinuation of treatment. 
V kliničnih študijah je bila pri bolnikih, zdravljenih s pegvisomantom (n = 550), večina neželenih učinkov blagih do zmernih, omejenega trajanja in ni zahtevala prekinitve zdravljenja.
Abbreviations: ALT = alanine aminotransferase; AST = aspartate transaminase; LT = liver test; ULN = upper limit of normal. 
Okrajšave: ALT = alanin-aminotransferaza; AST = aspartat-aminotransferaza; ZMN = zgornja meja normale.
However, monitor LTs weekly to determine if further increases occur (see below). 
Vendar pa tedensko spremljajte jetrne teste glede nadaljnjih zvečanj (glejte spodaj).
• Allergic reaction after administration (fever, rash, pruritus and, in severe cases, difficulty to breathe, rapid swelling of skin, requiring urgent medical attention). 
• alergijska reakcija po uporabi (vročina, izpuščaj, srbenje in v hudih primerih težave z dihanjem, hitro otekanje kože, zaradi katerih so potrebni nujni zdravstveni ukrepi);
It is important to keep using all your medicines as well as SOMAVERT unless you are told otherwise by your doctor, pharmacist or nurse. 
Pomembno je, da še naprej jemljete vsa svoja zdravila in tudi zdravilo SOMAVERT, razen če vam zdravnik, farmacevt ali medicinska sestra naročijo drugače.
If you forget to give yourself an injection you should inject the next dose as soon as you remember and then continue to inject SOMAVERT as prescribed by your doctor. 
Če si pozabite dati injekcijo, si naslednji odmerek injicirajte, čim se spomnite, potem pa z injiciranjem zdravila SOMAVERT nadaljujte tako, kot vam je predpisal zdravnik.
Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
Preobčutljivost na učinkovino ali katerokoli pomožno snov, navedeno v poglavju 6.1.
Pharmacotherapeutic group: Other anterior pituitary lobe hormones and analogues, ATC code: H01AX01. 
Farmakoterapevtska skupina: drugi hormoni prednjega režnja hipofize in sorodne učinkovine, oznaka ATC: H01AX01.
The most commonly reported adverse reactions occurring in  10% of patients with acromegaly treated with pegvisomant during the clinical trials were headache 25%, arthralgia 16% and diarrhoea 
Najpogosteje opisani neželeni učinki, ki so se v kliničnih preskušanjih pojavili pri  10 % bolnikov z akromegalijo, zdravljenih s pegvisomantom, so bili glavobol (25 %), artralgija (16 %) in diareja
How can I tell if there is any foam in the vial? 
Kako vem, da so v viali pene?
What SOMAVERT is and what it is used for 
Kaj je zdravilo SOMAVERT in za kaj ga uporabljamo
Pegvisomant is slowly eliminated from serum, with mean estimates of half-life generally ranging from 74 to 172 hours following either single or multiple-doses. 
Pegvisomant se iz seruma odstranjuje počasi; povprečne ocene razpolovnega časa na splošno so od 74 do 172 ur po posamičnem ali večkratnih odmerkih.
• The syringe and needle should NEVER be reused. 
• Brizge in igle ne smete NIKOLI ponovno uporabiti.
• Determine if cholelithiasis or choledocholithiasis is present, particularly in patients with a history of prior therapy with somatostatin analogs. 
• Ugotovite, ali je prisotna holelitiaza ali holedoholitiaza, še zlasti pri bolnikih, ki so se v preteklosti že zdravili z analogi somatostatina.
Do not spray the liquid directly onto the powder, as this creates foam. 
Ne brizgajte tekočine neposredno na prašek, saj tako nastanejo pene.
• Rapid swelling of skin and underlying tissue and inner lining (mucosa) of organs 
• hitro otekanje kože in podkožnega tkiva ter notranje obloge (sluznice) organov
Frequency Not Known (Cannot Be Estimated From Available Data) 
Neznana (ni mogoče oceniti iz razpoložljivih podatkov)
Do not use this medicine after the expiry date which is stated on the vial and the carton after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na viali in škatli.
This ensures that all air is removed from the syringe before you draw off the dose. 
Tako boste zagotovo odstranili ves zrak iz brizge, preden izvlečete odmerek.
• If liver injury is confirmed, the drug should be discontinued. 
• V primeru potrditve poškodbe jeter je treba zdravljenje z zdravilom prekiniti.
• Severe breathlessness (laryngospasm) 
• huda zasoplost (laringospazem)
• Clean the injection area with the alcohol swab as instructed by your healthcare provider. 
• Mesto injiciranja očistite z alkoholnim zložencem, kot vam je naročil zdravstveni delavec.
The pre-filled solvent syringe may be stored at room temperature. 
Napolnjene injekcijske brizge lahko shranjujete pri sobni temperaturi.
Uncommon (≥1/1,000 to < 
Občasni (≥ 1/1.000 in
A cohort of 38 acromegalic subjects has been followed in a long-term, open-label, dose-titration study for at least 12 consecutive months of daily dosing with pegvisomant (mean = 55 weeks). 
Kohorto 38 preskušancev z akromegalijo so spremljali v dolgoročni, odprti študiji s titriranjem odmerka vsaj 12 zaporednih mesecev vsakodnevne uporabe pegvisomanta (povprečje = 55 tednov).
Do not inject a double dose to make up for forgotten individual doses. 
Ne injicirajte dvojnega odmerka, če ste pozabili uporabiti prejšnjega.
• Continue swirling the liquid until all the powder has fully dissolved. 
• Nadaljujte z mešanjem tekočine, dokler se ves prašek ne raztopi.
A single Somavert pack containing: 
Eno pakiranje zdravila Somavert vsebuje:
• Clean the vial stopper with a fresh alcohol wipe, and leave it to dry completely. 
• Očistite zamašek viale s svežim alkoholnim zložencem in pustite, da se posuši.
• Decreased platelets in the blood, increased or decreased white cells in the blood, tendency to bleed. 
• zmanjšano število krvnih ploščic v krvi, zvečano ali zmanjšano število belih krvnih celic v krvi, nagnjenost h krvavitvam
• Only mix Somavert and the solvent when you are ready to inject your dose. 
• Zdravilo Somavert in vehikel zmešajte šele, ko ste pripravljeni na injiciranje odmerka.
The excretion of pegvisomant in breast milk has not been studied in animals. 
Izločanje pegvisomanta v materino mleko ni bilo preučeno na živalih.
• Do not treat with SOMAVERT until a comprehensive workup establishes the cause of the patient's liver dysfunction. 
• Ne zdravite z zdravilom SOMAVERT, dokler s celostnim diagnostičnim pregledom ne ugotovite vzroka motnje delovanja jeter pri bolniku.
Animal studies are insufficient with respect to effects on pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).The potential risk for humans is unknown. 
Študij na živalih o učinkih na nosečnost, razvoj zarodka/ploda, porod ali poporodni razvoj ni dovolj (glejte poglavje 5.3).
In the one reported incident of acute overdose, where 80 mg/day was administered for 7 days, the patient experienced a slight increase in fatigue and dry mouth. 
Opisan je en primer akutnega prevelikega odmerjanja pri uporabi 80 mg/dan 7 dni; bolnik je bil nekoliko bolj utrujen in je imel suha usta.
Statistically significant differences from placebo (p<0.05) were observed for improvements in the total signs and symptoms score for all dose groups compared to placebo. 
V vseh odmernih skupinah so ugotovili statistično pomembno (p < 0,05) razliko izboljšanja celotne ocene simptomov in znakov v primerjavi s placebom.
If you forget to use SOMAVERT 
Če ste pozabili uporabiti zdravilo SOMAVERT
* Excipient with known effect 
Pomožna snov z znanim učinkom
1/100 to <1/10 
 1/100 in < 1/10
Growth hormone-secreting pituitary tumours may sometimes expand, causing serious complications (for example, visual field defects). 
Hipofizni tumorji, ki izločajo rastni hormon, se včasih lahko zvečajo in povzročijo resne zaplete (npr. izpade v vidnem polju).
• Check that the plunger rod has not moved-if it has, then push it back all the way into the syringe. 
• Preverite, da se bat ni premaknil - če se je, ga do konca potisnite nazaj v injekcijsko brizgo.
Bubbles or air gaps that float to the top of the liquid should be pushed back out into the vial. 
Mehurčke ali zračne vrzeli, ki se dvigujejo na gladino, potisnite nazaj v vialo.
How to store SOMAVERT Contents of the pack and other information 
Shranjevanje zdravila SOMAVERT Vsebina pakiranja in dodatne informacije
• Release the pinched skin and pull the needle straight out. 
• Izpustite stisnjeno kožo in iglo izvlecite naravnost iz kože.
The injection must not be mixed in the same syringe or vial as any other medicine. 
Zdravila se v isti brizgi ali viali ne sme mešati z nobenim drugim zdravilom.
• Tiny air bubbles in the liquid are normal and are safe to inject. 
• Majhni zračni mehurčki v tekočini so običajni.
Treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF-I concentrations or was not tolerated. 
Zdravljenje odraslih bolnikov z akromegalijo, ki se na operacijo in/ali obsevanje niso ustrezno odzvali in pri katerih ustrezna farmakoterapija z analogi somatostatina ni normalizirala koncentracije IGF-I oz. takšne farmakoterapije niso prenašali.
Pegvisomant is not recommended during pregnancy (see section 4.6). 
Pegvisomanta ni priporočljivo uporabljati med nosečnostjo (glejte poglavje
The injection can be self-administered or given by another person, for example your doctor or his/her assistant. 
Injekcijo si lahko daste sami ali vam jo da kdo drug, npr. zdravnik ali medicinska sestra.
• Choose a different location within an area for each injection. 
• Za vsako injiciranje izberite drugo mesto znotraj predela injiciranja.
Absorption of pegvisomant following subcutaneous administration is slow and prolonged, and peak serum pegvisomant concentrations are not generally attained until 33-77 hours after administration. 
Absorpcija pegvisomanta po subkutani aplikaciji je počasna in podaljšana; največja koncentracija pegvisomanta v serumu je praviloma dosežena šele od 33 do 77 ur po uporabi.
What you need to know before you use SOMAVERT 
Kaj morate vedeti, preden boste uporabili zdravilo SOMAVERT
Do not use any other liquid to mix with Somavert. 
Za mešanje z zdravilom Somavert ne uporabljajte drugih tekočin.
Inhibition of growth hormone action with pegvisomant leads to decreased serum concentrations of insulin-like growth factor-I (IGF-I), as well as other growth hormone-responsive serum proteins such as free IGF-I, the acid-labile subunit of IGF-I (ALS), and insulin-like growth factor binding protein-3 (IGFBP-3). 
Zavrtje delovanja rastnega hormona s pegvisomantom povzroči zmanjšanje koncentracije insulinu podobnega rastnega faktorja I (IGF-I) v serumu, pa tudi drugih serumskih beljakovin, odzivnih na rastni hormon, npr. prostega IGF-I, kislinsko labilne podenote IGF-I (ALS) in beljakovine 3, ki veže insulinu podobni rastni faktor (IGFBP-3).
However, monitor LTs monthly to determine if further increases occur. 
Vendar pa mesečno spremljajte jetrne teste glede nadaljnjih zvečanj.
Is it OK to shake the vial if the powder is not dissolving? 
Ali lahko vialo stresem, če se prašek ni raztopil?
• If necessary, use a clean cotton ball and press lightly on the injection area. 
• Če je treba, uporabite čist kos vate in ga rahlo pritisnite na mesto injiciranja.
Dose-dependent, statistically significant reductions in mean IGF-I (p<0.0001), free IGF-I (p<0.05), IGFBP-3 (p<0.05) and ALS (p<0.05) were observed at all post-baseline visits in the pegvisomant treatment groups. 
V skupini, ki je prejemala pegvisomant, so na vseh poizhodiščnih pregledih ugotavljali od odmerka odvisno, statistično pomembno zmanjšanje povprečnega IGF-I (p < 0,0001), prostega IGF-I (p < 0,05), IGFBP-3 (p < 0,05) in ALS (p < 0,05).
Choose injection area 
Izberite mesto injiciranja
For storage conditions after reconstitution of the medicinal product, see section 6.3. 
Po pripravi: Za pogoje shranjevanja po pripravi zdravila glejte poglavje 6.3.
Other medicines and SOMAVERT 
Druga zdravila in zdravilo SOMAVERT